Ohio State University Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).
Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.
Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.
Top-decile sponsor footprint
Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
341 total, page 4 of 7
Young Adult EC Use and Respiratory Outcomes
NCT04395274
Evaluating E-Cigarette Nicotine Form, Concentration, and Flavors Among Youth
NCT05458895
Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery
NCT05583981
Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia
NCT05810714
Weight Loss Intervention for the Reduction of Cancer Risk and Health Disparities in Rural Ohio
NCT05040152
An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors
NCT05012176
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT04862585
Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer
NCT04938869
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
NCT06062901
Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
NCT04411849
Tango for Neuropathy Among Breast Cancer Survivors
NCT05114005
A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer
NCT05342571
Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer
NCT04269837
Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity
NCT04954885
Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
NCT04733495
Evaluating Anti-Tobacco Message Effectiveness Among Lesbian, Gay, Bisexual, and Transgender Young Adults
NCT05393869
Fatigue Reduction Diet in Lymphoma Survivors
NCT05327725
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT04205903
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT03715959
Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer
NCT05158452
Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures
NCT03502200
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
NCT05086705
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
NCT04312841
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
NCT04602026
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
NCT04597086
Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer
NCT05304793
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
NCT04120454
The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients
NCT05102773
Resiliency Among Older Adults Receiving Lung Cancer Treatment
NCT04229381
Addiction and Behavior Related to Menthol Cigarette Substitutes
NCT04844762
Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study
NCT04267874
HPV Vaccine Intervention for Young Sexual Minority Men
NCT04032106
Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors
NCT04454086
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
NCT03878199
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
NCT03858855
Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers
NCT04662645
Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs
NCT03691350
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03583424
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
NCT03654638
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
NCT03525925
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03552471
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
NCT03372720
Indocyanine Green Lymphangiography in Identifying Thoracic Duct During Neck Surgery
NCT03532581
Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations
NCT05264532
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
NCT03460483
Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study
NCT06534424
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
NCT02512497
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
NCT03307044
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
NCT03535701
Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
NCT03102866
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 59 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Ohio State University Comprehensive Cancer Center pipeline
77 recruiting of 341 indexed (23% open); 206 completed (60%).
Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).
Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 341 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
Sponsors near 23% open enrollment (± trial volume)
- University of Delaware · 23% recruiting · 106 trials
- University of Virginia · 22% recruiting · 449 trials
- University of Kansas Medical Center · 23% recruiting · 408 trials
- University of Oklahoma · 22% recruiting · 358 trials
Related
What to do with this Ohio State University Comprehensive Cancer Center page
341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.
- 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.